Depression and ischemic heart disease
Carlo A Pivato1, Rishi Chandiramani2, Marija Petrovic3
1Humanitas Research Hospital IRCCS, Rozzano-Milan, Italy; Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
Insights
Depression frequently affects patients with ischemic heart disease, increasing their risk of atherosclerosis and cardiac events. Early recognition and treatment of depression can improve outcomes for these patients.
Area of Science:
- Cardiology
- Psychiatry
- Internal Medicine
Background:
- Depression is highly prevalent in patients with ischemic heart disease (IHD).
- Depression is associated with increased risk of atherosclerosis and major cardiac events.
- The pathophysiology of depression and IHD is complex and interconnected.
Purpose of the Study:
- To review the epidemiology of depression in IHD patients.
- To summarize the pathophysiological mechanisms linking depression and IHD.
- To outline management strategies for depression in IHD.
Main Methods:
- Literature review of existing studies.
- Synthesis of evidence on epidemiology and pathophysiology.
- Analysis of treatment implications.
Main Results:
- Shared pathophysiological pathways include stress hormones, autonomic dysregulation, hemostasis, endothelial dysfunction, and inflammation.
- Depression impairs medication adherence in IHD patients.
- Evidence supports the link between depression and adverse cardiovascular outcomes.
Conclusions:
- Depression significantly impacts IHD prognosis and patient compliance.
- Integrated management of depression is crucial for improving IHD outcomes.
- Further research into shared mechanisms and targeted therapies is warranted.
Abstract:
Depression is common in patients with ischemic heart disease, and depressed patients are more likely to develop atherosclerosis and experience major cardiac events compared with the general population. The underlying pathophysiological mechanisms of these two diseases are highly interwoven and include an increased release of stress hormones, dysregulation of the autonomic nervous system, alterations of pathways related to primary and secondary hemostasis, endothelial dysfunction, and higher level of residual inflammation. Furthermore, depression negatively impacts compliance with medication regimens. As such, early recognition and treatment of depression provide the opportunity to improve outcomes of patients with ischemic heart disease. In the present review, we provide a summary of the evidence on the epidemiology, pathophysiology and management of depression in patients with ischemic heart disease.
More Related Videos
10:21Evaluation of Hydration Status by Bioelectrical Impedance Vector Analysis in Patients with Ischemic Heart Disease Undergoing Exercise Stress Test
Published on: September 22, 2023
04:38A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats
Published on: May 22, 2019
Related Concept Videos
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Depressive Disorders: Etiology
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Depression: Overview
Coronary Artery Disease IV: Preventive Measures
Depressive Disorders: MDD and Dysthymia
